Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 1 Patients characteristics and demographics

From: Impaired phagocytosis and reactive oxygen species production in phagocytes is associated with systemic vasculitis

  All patients (n = 104) Remission BVAS3 = 0 (n = 82) Disease activity BVAS3 > 1 (n = 22)
Age, years, median (range) 68 (20–86) 68 (25–84) 66 (20–86)
Disease duration, years, median (range) 7 (0–50) 7 (0–50) 1 (0–31)
GPA, % (n) 70 % (n = 73) 68 % (n = 56) 78 % (n = 18)
MPA, % (n) 22 % (n = 23) 24 % (n = 19) 17 % (n = 4)
EGPA, % (n) 8 % (n = 8) 8 % (n = 7) 4 % (n = 1)
MPO-ANCA, % (n) 30 % (n = 32) 33 % (n = 26) 26 % (n = 6)
PR3-ANCA, % (n) 59 % (n = 61) 56 % (n = 46) 70 % (n = 16)
BVAS3, median (range) 0 (0–16) 0 4 (1–16)
Leukocytes, 109/L, median (range)a 6.4 (3.0–13.7) 6 (3.2–13.7) 7.9 (3.0–12)
P-creatinine, μmol/L, median (range) 98 (54–646) 96 (59–635) 143 (54–646)
P-CRP, mg/L, median (range) 2.6 (<0.6–92) 2.6 (<0.6–27) 5.7 (<0.6–92)
Treatment b    
Prednisone, % (median dose of treated patients) 60 % (6.25 mg) 55 % (5 mg) 77 % (15 mg)
Azathioprine, % (n) 28 % (n = 29) 31 % (n = 26) 13 % (n = 3)
Mycophenolate mofetil, % (n) 8 % (n = 8) 10 % (n = 8) 0
Rituximab, % (n) 19 % (n = 20) 19 % (n = 17) 17 % (n = 3)
Methotrexate, % (n) 14 % (n = 15) 14 % (n = 11) 17 % (n = 4)
Cyclophosphamide, % (n) 11 % (n = 11) 7 % (n = 6) 27 % (n = 6)
  1. BVAS Birmingham Vasculitis Activity Score version 3, GPA granulomatosis with polyangiitis, MPA microscopic polyangiitis, EGPA eosinophilic granulomatosis with polyangiitis, MPO myeloperoxidase, ANCA anti-neutrophil cytoplasmic antibodies, PR3 proteinase 3, CRP C-reactive protein. aReference range 3.5–8.8 109/L. bThere were 14 patients who did not receive any treatment